Manufacturer of Controlled Substances; Notice of Registration, 10679-10680 [05-4203]

Download as PDF 10679 Federal Register / Vol. 70, No. 42 / Friday, March 4, 2005 / Notices manufacturer of Cocaine (9041), a basic class of controlled substance listed in Schedule II. The company plans to manufacture a cocaine derivative to be used as an intermediate for the production of Dopascan Injection. Cocaine derivatives are a Schedule II controlled substance in the cocaine basic class. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Guilford Pharmaceuticals, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Guilford Pharmaceuticals, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with State and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Schedule II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. Any other such applicant and any person who is presently registered with VerDate jul<14>2003 19:07 Mar 03, 2005 Jkt 205001 Dated: February 22, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–4202 Filed 3–3–05; 8:45 am] BILLING CODE 4910–13–P DEPARTMENT OF JUSTICE Drug Enforcement Administration DEPARTMENT OF JUSTICE Manufacturer of Controlled Substances; Notice of Registration Drug Enforcement Administration By Notice dated September 16, 2004, and published in the Federal Register on September 30, 2004, (69 FR 58542– 58533), Lifepoint, Inc., 10400 Trademark Street, Rancho Cucamonga, California 91730, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I and II: Drug Pursuant to section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 11, 2004, JFC Technologies, LLC, 100 West Main Street, Bound Brook, New Jersey 08805, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic class of controlled substances listed in Schedule II: Matthey Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed. BILLING CODE 4410–09–P By Notice dated November 22, 2004 and published in the Federal Register on December 6, 2004, (69 FR 70470), Johnson Matthey, Inc., Pharmaceutical Materials, 2003 Nolte Drive, West Deptford, New Jersey 08066, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic class of controlled substances listed in Schedule II. BILLING CODE 4410–09–P Diphenozylate (9170) .................... Hydrocodone (9193) ..................... Dated: February 23, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–4227 Filed 3–3–05; 8:45 am] Importer of Controlled Substances; Notice of Registration Dated: February 22, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–4198 Filed 3–3–05; 8:45 am] Drug DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than May 3, 2005. Schedule Phenylacetone (8501) .................. Raw Opium (9600) ....................... Concentrate of Poppy Straw (9670). II II II The company plans to import the listed controlled substances as raw materials for use in the manufacture of bulk controlled substances for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Johnson Matthey Inc. to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Johnson PO 00000 Frm 00089 Fmt 4703 Sfmt 4703 Drug Tetrahydrocannabinols (7370) ..... Amphetamine (1100) .................... Methamphetamine (1105) ............ Phencyclidine (7471) .................... Benzoylecgonine (9180) ............... Morphine (9300) ........................... Schedule I II II II II II The company plans to produce small quantities of controlled substances for use in drug test kits. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Lifepoint, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Lifepoint, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and E:\FR\FM\04MRN1.SGM 04MRN1 10680 Federal Register / Vol. 70, No. 42 / Friday, March 4, 2005 / Notices local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: February 23, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–4222 Filed 3–3–05; 8:45 am] Dated: February 22, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–4203 Filed 3–3–05; 8:45 am] DEPARTMENT OF JUSTICE BILLING CODE 4410–09–P Pursuant to 21 U.S.C. 958(1), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under 21 U.S.C. 952(a)(2)(b) authorizing the importation of such substances, provide manufacturers holding registrations for the bulk manufacture of the substances an opportunity for a hearing. Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on December 9, 2004, Lipomed Inc., One Broadway, Cambridge, Massachusetts 02142, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances: Drug Enforcement Administration Importation of Controlled Substances; Notice of Application DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances Notice of Application Pursuant to 21 CFR 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on December 9, 2004, Lin Zhi International Inc., 687 North Pastoria Avenue, Sunnyvale, California 94085, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed in Schedule II. Drug Schedule Oxycodone (9143) ........................ Hydrocodone (9193) ..................... II II The company plans to manufacture the listed controlled substances in bulk for use in analysis and drug test standards. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a) Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than May 3, 2005. VerDate jul<14>2003 19:07 Mar 03, 2005 Jkt 205001 BILLING CODE 4410–09–P Drug Schedule Cathinone (1235) .......................... Methaqualone (2565) ................... Gamma-Hydroxybutyric Acid (2010). Lysergic acid diethylamide (7315) Marihuana (7360) ......................... Tetrahydrocannabinols (7370) ..... Mescaline (7381) .......................... 3,4,5-Trimethoxyamphetamine (7390). 4-Bromo-2–5dimethoxyamphetamine (7391). 4-Methyl-2,5dimethoxyamphetamine (7395). 2,5-Dimethoxyamphetamine (7396). 2,5-Dimethoxy-4ethylamphetamine (7399). 3,4-Methylenedioxyamphetamine (7400). 3,4-Methylenedioxy-Nethylamphetamine (7404). 3,4-Methylenedioxymethamphetamine (7405). Psilocybin (7437) .......................... Psilocyn (7438) ............................. Acetyldihydrocodeine (9051) ........ Dihydromorphine (9145) ............... Heroin (9200) ............................... Tilidine (9750) ............................... Amphetamine (1100) .................... Methamphetamine (1105) ............ Amobarbital (2125) ....................... Secobarbital (2315) ...................... PO 00000 Frm 00090 Fmt 4703 Sfmt 4703 I I I I I I I I I I I I I I I I I I I I I II II II II Drug Phencyclidine (7471) .................... Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Benzoylecgonine (9180) ............... Hydrocodone (9193) ..................... Levorphanol (9220) ...................... Methadone (9250) ........................ Dextropropoxphene (9273) .......... Morphine (9300) ........................... Thebaine (9333) ........................... Oxymorphone (9652) ................... Alfentanil (9737) ........................... Fentanyl (9801) ............................ Schedule II II II II II II II II II II II II II II II II The company plans to import small reference standard quantities of finished commercial product from its sister company in Switzerland for distribution to its customers for drug testing and pharmaceutical research and development. Any manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file written comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than April 4, 2005. This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745–43746), all applicants for registration to import basic class of any controlled substance in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. E:\FR\FM\04MRN1.SGM 04MRN1

Agencies

[Federal Register Volume 70, Number 42 (Friday, March 4, 2005)]
[Notices]
[Pages 10679-10680]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-4203]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated September 16, 2004, and published in the Federal 
Register on September 30, 2004, (69 FR 58542-58533), Lifepoint, Inc., 
10400 Trademark Street, Rancho Cucamonga, California 91730, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of the basic classes of controlled 
substances listed in Schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)...............  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Phencyclidine (7471).......................  II
Benzoylecgonine (9180).....................  II
Morphine (9300)............................  II
------------------------------------------------------------------------

    The company plans to produce small quantities of controlled 
substances for use in drug test kits.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Lifepoint, Inc. to manufacture the listed basic classes of controlled 
substances is consistent with the public interest at this time. DEA has 
investigated Lifepoint, Inc. to ensure that the company's registration 
is consistent with the public interest. The investigation has included 
inspection and testing of the company's physical security systems, 
verification of the company's compliance with state and

[[Page 10680]]

local laws, and a review of the company's background and history. 
Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 
1301.33, the above named company is granted registration as a bulk 
manufacturer of the basic classes of controlled substances listed.

    Dated: February 22, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 05-4203 Filed 3-3-05; 8:45 am]
BILLING CODE 4410-09-P